Recyclable CRISPR/Cas9-mediated gene disruption and deletions in Histoplasma

被引:2
|
作者
Joehnk, Bastian [1 ,3 ]
Ali, Nebat [1 ]
Voorhies, Mark [1 ]
Walcott, Keith [1 ]
Sil, Anita [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94118 USA
[2] Chan Zuckerberg Biohub San Francisco, San Francisco, CA 94158 USA
[3] Formo Bio GmbH, Frankfurt, Germany
基金
美国国家卫生研究院;
关键词
CRISPR; genome editing; fungal pathogenesis; Histoplasma; CAPSULATUM; SYSTEM; DNA;
D O I
10.1128/msphere.00370-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Targeted gene disruption is challenging in the dimorphic fungal pathogen Histoplasma due to the low frequency of homologous recombination. Transformed DNA is either integrated ectopically into the genome or maintained extrachromosomally by de novo addition of telomeric sequences. Based on a system developed in Blastomyces, we adapted a CRISPR/Cas9 system to facilitate targeted gene disruption in Histoplasma with high efficiency. We express a codon-optimized version of Cas9 as well as guide RNAs from a single ectopic vector carrying a selectable marker. Once the desired mutation is verified, one can screen for isolates that have lost the Cas9 vector by simply removing the selective pressure. Multiple mutations can then be generated in the same strain by retransforming the Cas9 vector carrying different guides. We used this system to disrupt a number of target genes including RYP2 and SRE1, where loss-of-function mutations could be monitored visually by colony morphology or color, respectively. Interestingly, expression of two guide RNAs targeting the 5'- and 3'-ends of a gene allowed isolation of deletion mutants where the sequence between the guide RNAs was removed from the genome. Whole-genome sequencing showed that the frequency of off-target mutations associated with the Cas9 nuclease was negligible. Finally, we increased the frequency of gene disruption by using an endogenous Histoplasma regulatory sequence to drive guide RNA expression. These tools transform our ability to generate targeted mutations in Histoplasma. IMPORTANCE Histoplasma is a primary fungal pathogen with the ability to infect otherwise healthy mammalian hosts, causing systemic and sometimes life-threatening disease. Thus far, molecular genetic manipulation of this organism has utilized RNA interference, random insertional mutagenesis, and a homologous recombination protocol that is highly variable and often inefficient. Targeted gene manipulations have been challenging due to poor rates of homologous recombination events in Histoplasma. Interrogation of the virulence strategies of this organism would be highly accelerated by a means of efficiently generating targeted mutations. We have developed a recyclable CRISPR/Cas9 system that can be used to introduce gene disruptions in Histoplasma with high efficiency, thereby allowing disruption of multiple genes.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Development of CRISPR/Cas9-mediated gene disruption systems in Giardia lamblia
    Lin, Zi-Qi
    Gan, Soo-Wah
    Tung, Szu-Yu
    Ho, Chun-Che
    Su, Li-Hsin
    Sun, Chin-Hung
    PLOS ONE, 2019, 14 (03):
  • [2] CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells
    Wen, Luan
    Zhao, Changzhi
    Song, Jun
    Ma, Linyuan
    Ruan, Jinxue
    Xia, Xiaofeng
    Chen, Y. Eugene
    Zhang, Jifeng
    Ma, Peter X.
    Xu, Jie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (02)
  • [3] Fine mapping QTL regions by CRISPR/Cas9-mediated deletions
    Botkin, J. R.
    Young, N. D.
    Curtin, S.
    PHYTOPATHOLOGY, 2022, 112 (11) : 80 - 80
  • [4] Efficient CRISPR/Cas9-mediated gene disruption in the tetraploid protist Giardia intestinalis
    Horackova, Vendula
    Voleman, Lubos
    Hagen, Kari D.
    Petru, Marketa
    Vinopalova, Martina
    Weisz, Filip
    Janowicz, Natalia
    Markova, Lenka
    Motyckova, Alzbeta
    Najdrova, Vladimira
    Tumova, Pavla
    Dawson, Scott C.
    Dolezal, Pavel
    OPEN BIOLOGY, 2022, 12 (04)
  • [5] Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene
    Xu, Jie
    Livraghi-Butrico, Alessandra
    Hou, Xia
    Rajagopalan, Carthic
    Zhang, Jifeng
    Song, Jun
    Jiang, Hong
    Wei, Hong-Guang
    Wang, Hui
    Bouhamdan, Mohamad
    Ruan, Jinxue
    Yang, Dongshan
    Qiu, Yining
    Xie, Youming
    Barrett, Ronald
    McClellan, Sharon
    Mou, Hongmei
    Wu, Qingtian
    Chen, Xuequn
    Rogers, Troy D.
    Wilkinson, Kristen J.
    Gilmore, Rodney C.
    Esther, Charles R., Jr.
    Zaman, Khalequz
    Liang, Xiubin
    Sobolic, Michael
    Hazlett, Linda
    Zhang, Kezhong
    Frizzell, Raymond A.
    Gentzsch, Martina
    O'Neal, Wanda K.
    Grubb, Barbara R.
    Chen, Y. Eugene
    Boucher, Richard C.
    Sun, Fei
    JCI INSIGHT, 2021, 6 (01)
  • [6] CRISPR/Cas9-Mediated Gene Correction to Understand ALS
    Yun, Yeomin
    Ha, Yoon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
  • [7] Prevention of Muscle Wasting by CRISPR/Cas9-mediated Disruption of Myostatin In Vivo
    Wei, Yuda
    Chen, Yanhao
    Qiu, Yan
    Zhao, Huan
    Liu, Gaigai
    Zhang, Yongxian
    Meng, Qingyang
    Wu, Guohao
    Chen, Yixiong
    Cai, Xiaolong
    Wang, Hui
    Ying, Hao
    Zhou, Bin
    Liu, Mingyao
    Li, Dali
    Ding, Qiurong
    MOLECULAR THERAPY, 2016, 24 (11) : 1889 - 1891
  • [8] Comparison of gene disruption induced by cytosine base editing-mediated iSTOP with CRISPR/Cas9-mediated frameshift
    Dang, Lu
    Li, Guanglei
    Wang, Xinjie
    Huang, Shisheng
    Zhang, Yu
    Miao, Yuanxin
    Zeng, Lisi
    Cui, Shuzhong
    Huang, Xingxu
    CELL PROLIFERATION, 2020, 53 (05)
  • [9] Chlamydomonas POLQ is necessary for CRISPR/Cas9-mediated gene targeting
    Sizova, Irina
    Kelterborn, Simon
    Verbenko, Valeriy
    Kateriya, Suneel
    Hegemann, Peter
    G3-GENES GENOMES GENETICS, 2021, 11 (07):
  • [10] CRISPR/Cas9-mediated gene knockout to address primary hyperoxaluria
    Hubner, A.
    Wood, K.
    Dymek, Z.
    Odate, S.
    Shaw, L.
    Krumm, E.
    Dowell, A.
    Wood, K.
    Finn, J.
    Holmes, R.
    Knight, J.
    Burns, S.
    HUMAN GENE THERAPY, 2019, 30 (11) : A179 - A179